No Data
BEIGENE (06160) rises by 6.11% after winning the patent dispute in the USA.
Jingwu Financial News | BEIGENE (06160) is fluctuating strongly, as of this report, up 6.11%, at HKD 158.1, with a transaction amount of 0.618 billion HKD. In terms of news, BEIGENE announced that the US Patent and Trademark Office made a final written decision, declaring that Pharmacyclics LLC's rights to US Patent No. 11,672,803, which was challenged by BEIGENE during the post-grant review process, are completely invalid. On November 1, 2023, regarding the patent infringement suit filed by Pharmacyclics against BEIGENE concerning BRUKINSA.
Express News | Beigene Says Pharmacyclics Litigation Is Not Expected to Have Adverse Effect on Co's Production, Operation
Express News | Beigene Says Pharmacyclics Litigation Is Not Having Adverse Effect on Development, Sales of Brukinsa in U.S.
BEIGENE (06160.HK) issued 0.2147 million shares due to the vesting of restricted share units.
Gelonghui reported on April 30 that BEIGENE (06160.HK) announced that on April 29, 2025, it will issue 0.2147 million ordinary shares due to the vesting of restricted stock units granted under the equity plan (excluding company Directors).
BEIGENE (06160) won the patent dispute in the USA as the USPTO ruled that the Pharmacyclics patent is invalid.
BEIGENE (06160) announced that the USPTO made a final written decision regarding Phar...
BEIGENE's revenue growth in 2024, narrowing losses, and core products gaining global traction.
① The company achieved a revenue of 27.214 billion yuan for the year, with a year-on-year increase of 56.19%; the net income attributable to shareholders was -4.978 billion yuan, a decrease of 17.38% from the previous year; the net income excluding non-recurring items was -5.379 billion yuan, a year-on-year decrease of 17.38%; ② The revenue share of Baiyueze and Baizean continues to expand, driving the company's revenue growth.
